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Abstract
Background: Peroxisome proliferator-activated receptor (PPAR)g may be a key regulator of connective tissue
deposition and remodeling in vivo. PPARg expression is reduced in dermal fibroblasts isolated from fibrotic areas of
scleroderma patients; PPARg agonists suppress the persistent fibrotic phenotype of this cell type. Previously, we
showed that loss of PPARg expression in fibroblasts resulted in enhanced bleomycin-induced skin fibrosis. However,
whether loss of PPARg expression in skin fibroblasts affects cutaneous tissue repair or homeostasis is unknown.
Results: Mice deleted for PPARg in skin fibroblasts show an enhanced rate of dermal wound closure, concomitant
with elevated phosphorylation of Smad3, Akt and ERK, and increased expression of proliferating cell nuclear
antigen (PCNA), collagen, a-smooth muscle actin (a-SMA) and CCN2. Conversely, dermal homeostasis was not
appreciably affected by loss of PPARg expression.
Conclusion: PPARg expression by fibroblasts suppresses cutaneous tissue repair. In the future, direct PPARg
antagonists and agonists might be of clinical benefit in controlling chronic wounds or scarring, respectively.
Background
If the dermis is injured, specialized fibroblasts called
myofibroblasts repopulate the wound and synthesize
and remodel new connective tissue [1]. Wound repair is
very complex and dynamic, involving the interactions of
multiple cell types and growth factors/cytokines; dysre-
gulation of this process results in chronic wounds or
fibrosis [2]. Thus, understanding the molecular mechan-
isms controlling the normal tissue repair program is
likely to be of clinical relevance.
Expression of the nuclear receptor peroxisome prolif-
erator-activated receptor (PPAR)-g is reduced in dermal
fibroblasts isolated from fibrotic lesions of patients with
t h ea u t o i m m u n ec o n n e c t i v et issue disease scleroderma
(systemic sclerosis, SSc); moreover, the PPARg agonist
rosiglitazone reverses the persistent fibrotic phenotype
of this cell type [3]. Normally, PPAR-g is bound to the
retinoid X receptor (RXR) and co-repressors, preventing
its binding to DNA; however, upon receptor ligation,
the co-repressors are displaced from the PPAR-g/RXR
complex allowing PPAR-g to bind PPAR-g response
elements in the promoters of target genes [4]. The
PPAR/RXR transcriptional complex plays a critical role
in maintaining energy balance, which is dysregulated in
conditions such as obesity, diabetes, and atherosclerosis
[4].
An increasing body of evidence also suggests that
PPAR-g p l a y sak e yr o l ei nc o n n e c t i v et i s s u et u r n o v e r ,a
key process involved with tissue remodeling [5]. Both in
vivo and in vitro,P P A R - g agonists inhibit basal and
transforming growth factor (TGF)-b-induced collagen
deposition and myofibroblast differentiation [6,7].
Although loss of PPARg expression in cultured mouse
embryonic fibroblasts results in enhanced, constitutive
Smad3 phosphorylation and collagen production [8],
loss of PPARg expression in cultured adult mouse fibro-
blasts appears to be insufficient to result in either Smad
3 activation or collagen production [9]. Instead, adult
dermal fibroblasts lacking PPARg expression show
enhanced sensitivity to exogenously added TGFb in
terms of enhanced phosphorylation of Smad3 and
expression of collagen/a-SMA mRNA [9]. Collectively,
these data strongly suggest that PPARg may play a role
in fibrosis by enhancing cellular responses to TGFb.
Recently, we showed that mice harboring a fibroblast-
specific deletion for PPARg displayed an enhanced
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[9]. These observations suggest that PPARg might be an
important regulator of cutaneous tissue repair and
homeostasis in vivo; however, this hypothesis has yet to
be tested. Herein, we subject mice harboring a fibro-
blast-specific deletion of PPARg to the dermal punch
model of cutaneous tissue repair. Moreover, we assess
whether loss of PPARg expression by skin fibroblasts
affects dermal homeostasis. Our results reveal new
insights into the role PPARg plays in fibroblast biology.
Results
Loss of PPARg expression in skin results in faster wound
closure
Mice deleted for PPARg in fibroblasts (K/K) and wild-
type littermate control (C/C) mice were generated and
genotyped as previously described [9] (Figure 1A).
Results were verified using Western blot and indirect
immunofluorescence analysis of skin using an anti-
PPARg antibody (Figure 1B, C). To examine whether
loss of PPARg expression in skin fibroblasts affected
tissue repair, we subjected mice harboring a fibroblast-
specific deletion for PPARg (K/K) and wild-type litter-
mate control mice (C/C) to the dermal punch model of
cutaneous tissue repair. PPARg knockout mice (K/K)
showed significantly increased wound closure three
days, five days and seven days post-wounding; however,
in both sets of mice, wound closure was essentially com-
plete 10 days post-wounding (Figure 2A, B). The fact
that mice harboring a fibroblast-specific deletion for
PPARg (K/K) showed an increased rate of tissue repair
was confirmed when skin of mice (seven days post-
wounding) were examined histologically using H & E
staining (Figure 3A). Thus, in skin, loss of PPARg
increased the kinetics of wound closure
As loss of PPARg resulted in an enhanced rate of tis-
sue repair, we assessed whether loss of PPARg also pro-
moted collagen deposition. Blind histological analysis of
trichrome-stained sections showed a greater collagen
score in wounded PPARg (K/K) compared to control
(C/C) mice (Figure 3B, C). Assessment of collagen con-
tent using an anti-type I collagen antibody (Figure 3D,
E) further confirmed that animals deficient in PPARg
possessed elevated collagen levels at day 7 post wound-
ing. We then assessed the effect of loss of PPARg on
myofibroblast induction. Immunohistochemical analysis
showed greater expression of a-SMA in day 7 and day
10 wounds of PPARg knockout (K/K) mice compared to
control (C/C) mice (Figure 4A, B). Western blot analysis
on protein samples prepared from control and bleomy-
cin-treated animals further confirmed elevated a-SMA
production in day 7 wounds of PPAR-deficient (C/C)
mice compared to control (K/K) mice (Figure 4C).
Fewer neutrophils were found in the wounds of PPAR-
deficient (C/C) mice compared to control (K/K) mice
(Figure 4D), consistent with the increased rate of wound
resolution observed in these mice. Furthermore, PCNA
(a marker of cell proliferation) and CCN2 (a marker of
tissue repair and fibrosis) expression were also signifi-
cantly induced in the skin of day 7 and day 10 PPAR
-deficient (C/C) mice compar e dt oc o n t r o l( K / K )m i c e
(Figure 5A, B). Similarly, elevated CCN2 mRNA expres-
sion was observed in PPAR-deficient fibroblasts (Figure
5C). Intriguingly, troglitazone, a PPARg agonist,
decreased CCN2 mRNA expression in both wild-type
and PPARg-deficient fibroblasts (Figure 5C) suggesting
that troglitazone operates through PPAR-independent
mechanisms (Figure 5C).
In skin fibroblasts, loss of PPARg has been shown to
result in enhanced phosphorylation of Smad3 in
response to bleomycin or TGFb [9]. Consistent with
these data, we showed, using indirect immunofluores-
cence with an anti-phospho-Smad3, that Smad3 phos-
phorylation was enhanced seven days post-wounding in
PPARg-deficient animals (Figure 6, p-Smad3). Moreover,
Figure 1 The deletion of PPARg in skin fibroblasts. (A) Mice
homozygous for loxP-PPARg and hemizygous for an allele enabling
a tamoxifen-dependent cre recombinase to be expressed under the
control of a fibroblast-specific collagen type I promoter/enhancer
were injected with tamoxifen or corn oil to generate mice deleted
(K/K) or not (C/C) for PPARg in fibroblasts. PCR genotyping of PPARg
WT (C/C) or PPARg KO (K/K) mice. The upper panel shows the PCR
result using primers detecting cre (approximately 650 bp band); the
bottom panel shows the PCR result with specific primers which
amplify Exon I and Exon II-deleted PPARg after tamoxifen injection
(approximately 350 bp band). (B) Western blot analysis of WT (C/C)
and PPARg KO (K/K) fibroblasts with an anti-PPARg antibody. (C)
Indirect immunofluorescence analysis of WT (C/C) and PPARg KO (K/
K) mice skin samples (original magnification × 40, bar = 25 μm)
using an anti- PPARg antibody. Red = PPAR gamma; Blue = DAPI.
DAPI, 4’,6-diamidino-2-phenylindole; PPARg, peroxisome proliferator-
activated receptor-g.
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phosphorylated downstream of TGFb and has previously
been shown to be activated in fibrosis and to be modi-
fied by PPARg [10-14], was also observed in the skin of
day 7 and day 10 wounds of PPARg-deficient animals
(Figure 6, p-Akt). Finally, enhanced phosphorylation of
ERK, a protein that is also phosphorylated downstream
of TGFb and shown to be modified by PPARg [14-17],
was also observed in the skin of day 7 and day 10
wounds of PPARg-deficient animals (Figure 6, p-ERK).
Collectively, these data indicate that loss of PPARg
expression in skin results in elevated pro-fibrotic
signaling.
Loss of PPARg does not appreciably affect dermal
homeostasis
A priori, we would have expected that, as loss of PPARg
resulted in increased Smad3 and Akt phosphorylation in
response to bleomycin or punch wounding [9], this
report, loss of PPARg expression by itself might have
been sufficient to result in skin fibrosis. However,
PPARg-deficient skin did not show significant alterations
in skin thickness or matrix accumulation even four
months after the PPARg gene was deleted (Figure 7A,
B).
Collectively, our results indicate that, in vivo,P P A R g
normally acts in dermal fibroblasts to suppress fibro-
genic responses.
Discussion
In this study, we tested the effect of loss of PPARg in
dermal fibroblasts on cutaneous tissue repair in vivo.
PPARg-deficient mice showed enhanced responsiveness
to tissue injury, as shown by increased wound closure
on days three, five, seven and ten post-wounding,
increased collagen production, the appearance of a-
SMA-expressing myofibroblasts, elevated CCN2 expres-
sion and enhanced Smad3/Akt phosphorylation. These
results are consistent with previous observations that
PPARg-deficient fibroblasts showed enhanced sensitivity
to TGFb1a n dt h a tP P A R g-deficient mice showed
increased susceptibility to bleomycin-induced skin fibro-
sis [8,9]. These data also agree with prior studies show-
ing that, in fibroblasts, PPARg agonists block TGFb-
induced a-SMA and collagen expression [6]. Moreover,
we showed that, although CCN2 mRNA was elevated in
PPARg-knockout fibroblasts, troglitazone suppressed
CCN2 mRNA in both wild-type and PPARg-knockout
fibroblasts. Although it is possible that these PPARg
agonists were active due to the small residual expression
of PPARg in PPARg knockout fibroblasts, these data do
not exclude the notion that thiazolidinediones such as
troglitazone have potent ‘off-target’ effects independent
Figure 2 Wound closure is faster in PPARg KO (K/K) mice than
WT (C/C) mice. (A) Photography of wound sites at different time
points after wounding (N ≥ 12 for each time point, four wounds for
each mouse) (B) Quantification of wound size at different time
points after wounding. Asterisks indicate significant differences
between WT and KO groups (** = P < 0.01; *** = P < 0.001). D, day.
PPARg, peroxisome proliferator-activated receptor-g.
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suggest that PPARg normally suppresses fibrogenic
responses in vivo and also support the notion that devel-
oping novel classes of direct PPARg agonists/antagonists
is warranted.
We found that long-term (up to four months) deletion
of PPARg did not appreciably affect dermal homeostasis.
This result is consistent with our previous data showing
that mice deficient in PPARg expression in fibroblasts
(approximately six weeks post-deletion of PPARg),
although possessing enhanced susceptibility to bleomy-
cin-induced skin fibrosis, possessed no detectable altera-
tions in skin structure [9]. PPARg is known to
upregulate the tumor suppressor PTEN; loss of PTEN
expression by dermal fibroblasts results in skin fibrosis
due to an increase in Akt phosphorylation [13,18]. Intri-
guingly, we found that PTEN expression was increased
and not decreased in the dermis of PPARg knockout
mice (data not shown). These observations suggest that
PPARg knockout mice may upregulate PTEN expression
to compensate for the loss of PPARg expression by der-
mal fibroblasts and provide a plausible explanation why
dermal homeostasis was not appreciably altered in
PPARg knockout mice and injury, whether caused by
bleomycin or by dermal punch wounding, is required to
elicit a phenotype in PPARg knockout animals.
Figure 3 Histological analysis of PPARg KO (K/K) mice and WT (C/C) wound tissue. (A) H&E and (B) trichrome staining of day 7 wounds (C/
C: N = 10; K/K: N = 12, original magnification × 5, bar = 200 μm). The arrow indicates wound width. (C) The collagen content in each section
was assessed by three blinded observers using the following assessment criteria: 0 signifies no collagen fibers, 1 signifies a few collagen fibers, 2
signifies a moderate amount of collagen fibers, and 3 signifies an excessive amount of collagen fibers. (D) Immunofluorescence analysis using an
anti-type I collagen antibody. (WT: N = 10; KO: N = 12, original magnification × 20, bar = 50 μm). Red-PPARg; Blue-DAPI. (E) Quantification of
type collagen I protein expression in wound tissues at Day 7 after wounding. *** = significant difference between C/C-WT and K/K-KO groups (P
< 0.001). DAPI, 4’,6-diamidino-2-phenylindole; PPARg, peroxisome proliferator-activated receptor-g Loss of PPARg results in enhanced collagen, a-
SMA, PCNA and CCN2 expression.
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In summary, our studies examining the involvement in
PPARg in skin indicate that PPARg normally acts in
fibroblasts to retard tissue repair. These results suggest
that direct PPARg agonists and antagonists might be
used to control the tissue repair program, for example,
by suppressing scarring or by promoting the closure of
chronic wounds.
Methods
Generation of PPARg conditional knockout mice
Mice, hemizygous for an allele expressing tamoxifen-indu-
cible Cre-recombinase (under the control of a fibroblast-
specific regulatory sequence from the proa2(I) collagen
gene [19]) and homozygous for a loxP-PPARg allele, were
generated as described previously [9]. Mice deleted (K/K)
or not (C/C) for PPARg in fibroblasts were generated by
treating three-week-old mice each day for five days with
tamoxifen (4-hydroxitamoxifen, Sigma, St. Louis, MO,
USA) in corn oil (0.1 ml of 10 mg/ml) or corn oil. Deletion
of PPARg was verified by PCR genotyping (Jackson
Laboratories, Bar Harbor, ME, USA).g All animal proto-
cols were approved by the regulatory authority of the
appropriate experimental animal committee.
Cell culture, immunofluorescence and Western analysis
Dermal fibroblasts, isolated from explants (four- to six-
week-old animals) as described, were subjected to
Figure 4 Alpha-SMA expression is enhanced in PPARg KO (K/K) wound tissue (day 7 and day 10 post-wounding). (A) Indirect
immunofluorescence analysis of WT (C/C) and PPARg KO (K/K) mice with an anti-a-SMA antibody (C/C: N = 10; K/K: N = 12, original
magnification × 20, bar = 50 μm). Green, a-SMA; Blue, DAPI. (B) Quantification of a-SMA expression intensity in wound tissues at day 7 and day
10 after wounding. (C) Western blot of a -SMA expression in WT (C/C) and PPARg KO (K/K) wound tissues at day 7 after wounding. GAPDH =
loading control. (D) Indirect immunofluorescence analysis of WT (C/C) and PPARg KO (K/K) mice with an anti-neutrophil antibody (C/C: N = 10;
K/K: N = 12, original magnification × 20, bar = 100 μm). Red, neutrophils; Blue, DAPI. (E) Quantification of neutrophils in wound tissues at day 7
after wounding. Asterisks indicate a significant difference between C/C and K/K groups (** = P < 0.01; *** = P < 0.001). DAPI, 4’,6-diamidino-2-
phenylindole; PPARg, peroxisome proliferator-activated receptor-g.
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Page 5 of 9Figure 5 PCNA and CCN2 expression is enhanced in PPARg KO (K/K) fibroblasts. Indirect immunofluorescence analysis of WT (C/C) and
PPARg KO (K/K) mice (day 7 and 10 post-wounding) with (A) an anti-PCNA antibody and (B) an anti-CCN2 antibody (C/C: N = 10; K/K: N = 12,
original magnification × 20, bar = 50 μm). Red, CCN2;Blue, DAPI. *** = indicates significant difference between C/C and K/K groups (P < 0.001).
(C) Real time PCR analysis of WT (C/C) and PPARg KO (K/K) fibroblasts treated with or without troglitazone (40 μM, 24 hours). Primers detecting
CCN2 and 18S mRNAs were used. Expression relative to CCN2 expression in untreated WT (C/C) fibroblasts is shown. Average +/- standard
deviation (N = 3) is shown. ** = significant difference between groups (P < 0.01). Note that CCN2 mRNA expression was elevated in (K/K)
fibroblasts; troglitazone (+trog) reduced CCN2 mRNA expression in both (C/C) and (K/K) fibroblasts indicating that troglitazone operated
independent of PPARg. DAPI, 4’,6-diamidino-2-phenylindole; PCNA, proliferating cell nuclear antigen.; PPARg, peroxisome proliferator-activated
receptor-g Loss of PPARg results in enhanced Smad3, Akt and ERK phosphorylation.
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appropriate secondary antibody (Jackson Immunore-
search, West Grove, PA, USA) as described [9]. Photo-
graphy (Zeiss Axiphot) was performed using a digital
camera (Empix, Mississauga, ON, Canada). For some
assays, cells were lysed in 2% SDS, proteins quantified
(Fisher, Nepean, ON, Canada) and subjected to Western
blot analysis [9]. Antibodies used were: anti-a-SMA
(Sigma,1:3000), anti-b-actin (1:5000, Sigma) and anti-
PPARg (Santa Cruz, Santa Cruz, CA, USA,1:500).g
Figure 6 Elevated p-Akt, p-Smad3 and p-Erk staining in PPARg KO (K/K) wound tissue (day 7 and day 10 post-wounding).I n d i r e c t
immunofluorescence analysis with anti-, anti-p-Smad3 and anti-p-Erk antibodies, as indicated, in wound tissues day7 and day 10 post-wounding
(C/C: N = 10; K/K: N = 12, original magnification × 20, bar = 50 μm). p-Akt, p-Smad3 and p-Erk expression intensity, respectively, are shown.
Asterisks indicate a significant difference between C/C and K/K groups (** = P < 0.01; *** = P < 0.001). PPAR, peroxisome proliferator-activated
receptor-g.
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Type Culture Collection, Manassas, VA, USA). Cells
were grown in (D)MEM, 10% fetal bovine serum (Life
Technologies, Burlington, ON, Canada).
Assessment of collagen content
To assess the effects of PPARg deletion on collagen
synthesis, trichrome collagen stain was used. Collagen
content in each section was assessed by three blinded
observers using the following assessment criteria: 0 sig-
nifies: no collagen fibers; 1 signifies: few collagen fibers;
2 signifies: moderate amount of collagen fibers; 3 sig-
nifies: excessive amount of collagen fibers.
Immunohistochemistry
Non-specific immunoglobulin G (IgG) binding was
blocked by incubating sections with BSA (0.1%) in PBS
for 1 hour and then incubated with primary antibody in
a humidified chamber and left overnight at 4°C. Next,
sections were washed and incubated with a secondary
antibody for 1 hour. Primary antibodies used were:
PPARg (Santa Cruz, Rabbit, sc-7196, 1:500) PTEN (Cell
Signaling, Pickering, ON, Canada, #9559, Rabbit, 1:500)
CCN2 (Abcam, Cambridge, MA, USA, ab6992, Rabbit,
1:250), a-SMA (Sigma, A5228, mouse, 1:2000); ColIa2
(Santa Cruz, sc-28654, rabbit, 1:500), PCNA: (Abcam,
ab2426-1, rabbit, 1:500); p-SMAD3: (Abcam, rabbit,
ab52903, 1:200); p-AKT (Rockland Immunochemicals,
Gilbertsville, PA, USA, 200-301-268, mouse), (1:500); p-
ERK (Cell Signaling, #9101, rabbit, 1:500) and neutrophil
marker (Santa Cruz, sc-59338, rat,1:100). Secondary
antibodies (Jackson Immunoresearch, 1:400) were:
Dylight 488 conjugated donkey anti-mouse (711-485-
150); Dylight 594 conjugated donkey anti-rabbit (711-
485-152); Dylight 594 conjugated donkey anti-mouse
(715-515-150) and Dylight 594 conjugated donkey anti-
rat (712-516-150).
Real-time PCR
Real-time PCR to detect the expression of target genes
was performed essentially as previously described
[20,21]. Cells were cultured until 50% confluence and
treated for 24 hours with dimethyl sulfoxide (DMSO) or
troglitazone (40 μM, EMD Biosciences, Billerica, MA,
USA) and total RNA was isolated (RNeasy; QIAGEN,
Toronto, ON, Canada). Total RNA (25 ng) was reverse
transcribed, amplified using Taq-Man Assays-on-
Demand in the presence One-Step MasterMix and
detected using the ABI Prism 7900 HT sequence detec-
tor (Life Technologies). Triplicate samples were run,
and expression values for CCN2 were standardized to
values obtained with control 18S primers using the
ΔΔCt method.
Statistics
Statistical analysis was done using one way analysis of
variance (ANOVA) and Tukey’s post-hoc test on Graph-
pad Prism 4 software.
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